A pilot study published in Cancer Medicine in May 2026 demonstrates that a modified therapeutic regimen featuring finite-duration venetoclax and azacitidine combined with umbilical cord blood infusion improves clinical outcomes for frail elderly patients with untreated acute myeloid leukemia (AML). Continuous venetoclax-azacitidine therapy is currently the major intervention for older or unfit patients, but the new research evaluates a finite-duration approach paired with decitabine, intermediate-dose cytarabine, and subsequent cord blood transfusion.
Study Design and Patient Cohort
According to data published by researchers at The First Affiliated Hospital, Zhejiang University School of Medicine, the single-center pilot study evaluated 16 elderly AML patients who underwent the treatment regimen between March 2021 and May 2024. Among the participants, 7 out of the 16 individuals presented at adverse risk. The median follow-up period reached 53.6 months, with a 95% confidence interval ranging from 36.2 to 71.0 months, as detailed in the findings.
The treatment protocol utilized venetoclax and azacitidine for both induction and maintenance phases. For consolidation therapy, patients received intravenous decitabine at 20 milligrams per square meter on days one through three, followed by intermediate-dose cytarabine at 1.0 gram per square meter every 12 hours on days four and five. On day seven, patients underwent an umbilical cord blood infusion scaled to 1.5% ± 25% × 107/kg.
Clinical Outcomes and Survival Rates
The research tracked multiple endpoints, including duration of response, overall survival, and treatment safety. Researchers recorded a median venetoclax cycle number prior to disease relapse of 5, with an interquartile range of 4 to 6 cycles.
The median duration of response reached 17.4 months, accompanied by a 1-year duration of response rate of 68.8% and a 2-year rate of 35.2%. Overall survival analysis revealed a median overall survival time of 24.9 months, with 1-year and 2-year overall survival rates of 100% and 55.6%, respectively. Notably, among the 8 patients identified with IDH1 or IDH2 mutations, 4 experienced sustained remission, maintaining a 1-year overall survival rate of 100%. Hematological and non-hematological toxicities remained manageable throughout the consolidation phase.
Implications for Unfit AML Patients
While continuous venetoclax-azacitidine offers an alternative, moderate chemotherapy utilizing finite-duration dosing could achieve comparable or superior efficacy to infinite-duration VA. The addition of umbilical cord blood transfusion is designed to improve clinical safety for elderly patients.
The study authors conclude that this modified intervention demonstrates prolonged survival, particularly among patients harboring IDH mutations. The approach provides significant clinical value for elderly patients with untreated acute myeloid leukemia who are unfit for standard treatments.
Related reading